Review anchor
Stimulator of interferon genes protein
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Stimulator of interferon genes protein
CHEMBL4523377
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Stimulator of interferon genes protein as ChEMBL target CHEMBL4523377, mapped to UniProt Q86WV6. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4523377
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q86WV6
Stimulator of interferon genes protein
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Stimulator of interferon genes protein matters
Stimulator of interferon genes protein is reviewed as Stimulator of interferon genes protein (UniProt Q86WV6); Stimulator of interferon genes protein shows clinical signal disease relevance led by head and neck malignant neoplasia. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 1601 compounds, and 654 assays, with lead potency reaching pChEMBL 10.2.
Protein context
Stimulator of interferon genes protein
Stimulator of interferon genes protein Sequence length is 379 aa.
Review this target as Stimulator of interferon genes protein, mapped to UniProt Q86WV6. Sequence length is 379 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q86WV6
Protein
Disease context
head and neck malignant neoplasia
Stimulator of interferon genes protein shows clinical signal disease relevance led by head and neck malignant neoplasia. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include ADU-S100.
Start review with head and neck malignant neoplasia because it currently carries clinical signal support. Linked drugs include ADU-S100. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 1601 compounds, and 654 assays for this target. The dominant activity type is EC50. CHEMBL5188233 is the current potency anchor at pChEMBL 10.2.
Use CHEMBL5188233 as the tractability anchor when discussing potency (pChEMBL 10.2).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 10.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Stimulator of interferon genes protein matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q86WV6, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why head and neck malignant neoplasia is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1601
Total Compounds
654
Total Assays
1
Approved Drugs
IC50: 751.0, KI: 35.0, EC50: 1854.0, KD: 181.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5188233
|
10.2 | Kd | — |
|
|
No preferred name
CHEMBL5201766
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL4465054
|
10.0 | Kd | — |
|
|
No preferred name
CHEMBL6003926
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL5967512
|
9.7 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PALBOCICLIB
CHEMBL189963
|
2015 |
Source Header